Galderma’s updated ALASTIN eye product comes with 12-week appearance results and collagen claims. We assess the findings and study limitations.
On October 26, 2026, Galderma announced the U.S. launch of ALASTIN Restorative Eye Complex with TriHex+™. Galderma says the updated formula is intended for the upper eyelid, under-eye area, and crow’s-feet area. The company describes it as the third product in ALASTIN’s TriHex+ portfolio.
The announcement pairs a collagen-and-elastin rationale with reported improvements in how the eye area looks. For readers, the central task is to distinguish the proposed biological action from the outcomes actually assessed.
Galderma describes TriHex+ as combining its TriHex Technology® with proprietary Octapeptide-45. The company says TriHex supports the body’s natural collagen and elastin production. It describes Octapeptide-45 as supporting the skin’s production of high-molecular-weight hyaluronic acid.
According to the announcement, the formula also includes Acetyl Tetrapeptide-2 and a proprietary dill-and-blackberry blend. These ingredient descriptions belong to the company’s explanation of its formula. They should be read as attributed product claims rather than independent biological findings.
Galderma Chief Scientific Officer Alan D. Widgerow said the product was designed to address the upper eyelid, under-eye area, and crow’s feet individually. His comments explain the company’s rationale for treating these as distinct areas of concern.
The evaluation results address a different question: what changes did investigators record in participants’ appearance? Keeping that question separate from the proposed mechanism makes the announcement easier to interpret. A claim about supporting collagen production concerns biological activity. An investigator’s rating of fine lines concerns an assessed appearance outcome.
Both may be relevant to evaluating a skincare product. They are not interchangeable measures.
Galderma reports a 12-week evaluation involving 29 participants aged 35 to 70. Participants had moderate-to-severe signs of aging around the eyes.
The company says assessments included clinical grading and photography. Participants also completed self-assessments, and investigators used hydration and elasticity instruments.
At week 12, Galderma reports these investigator-grading results:
The release gives p<0.0001 for each result. These percentages describe reported changes in investigator grading. They are not the percentages of participants who experienced an improvement.
The figures also belong to the population evaluated. They should not automatically be applied to people with different concerns or less pronounced visible changes. Outcomes in everyday use may differ from those recorded during an evaluation, so the percentages are not a forecast of an individual user’s response.
Galderma attributes the results to “ALASTIN data on file.” Its release does not identify a peer-reviewed publication or independent replication. Secondary reporting of this launch largely repeats the announcement and evaluation results rather than supplying independent expert assessment.
The release does not provide a control or comparator. It also omits blinding details and study registration. The full protocol and adverse-event information are not included. Without those disclosures, readers cannot adequately assess the study design or compare the reported changes with no treatment or another product.
These are gaps in the announcement’s reporting. They do not establish that every undisclosed feature was absent from the underlying evaluation. The distinction matters because an incomplete public account and a demonstrated methodological failure are not the same thing.
The evaluation is also small. The reported statistical significance does not establish how noticeable the changes would be to consumers or how long they would last. Those questions require evidence beyond the significance values supplied in the release.
The missing adverse-event information leaves a separate question about safety unanswered by this announcement. Appearance improvements alone are not a substitute for information about tolerability.
Most importantly for the collagen claim, the release does not provide independent evidence establishing that the finished product increases collagen or elastin in users. Investigator-graded changes in fine lines and puffiness should therefore remain appearance findings. Relabeling them as direct proof of collagen or elastin production would go beyond the disclosed evidence.
Galderma says the product will initially be sold in the U.S. through authorized healthcare providers and provider microsites. The announcement gives neither a price nor detailed use instructions. It supports an informed provider conversation rather than a personal product-use plan.
For someone considering the formula, useful questions include:
These questions keep the discussion tied to the evidence without turning the launch announcement into a recommendation to use the product. Provider-based availability describes where a product is offered. Suitability remains a personal decision that deserves qualified guidance.
It also helps to begin with the particular visible concern being assessed. A result involving puffiness answers a different question from a result involving upper-eyelid lines. There is no need to combine them into a single claim about overall skin renewal.
The same discipline applies when weighing other collagen-related beauty claims. Start with the outcome measured and the evidence supporting it. Then consider whether the proposed explanation has been tested separately.
This launch offers a focused research question: do improvements in investigator-rated appearance correspond to measurable collagen and elastin changes with the finished formula?
Answering that question would help connect the product’s biological rationale with its reported appearance outcomes. It would also make the collagen language more useful to readers assessing the formula on its evidence rather than its positioning.
For now, the clearest reading is straightforward: Galderma has announced an updated eye product and reported specific appearance improvements in its evaluation. Those results deserve to be described accurately, without expanding them into a broader claim about rebuilding skin structure.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
